Key result
Tirofiban linked to acute profound thrombocytopenia after primary angioplasty in a single case.
Case Report (n=1)
Tirofiban, a glycoprotein IIb/IIIa inhibitor, can induce acute profound thrombocytopenia following primary angioplasty, despite being associated with a lower incidence than abciximab.
Glycoprotein IIb/IIIa inhibitors are used in the acute coronary syndromes and percutaneous coronary intervention as antiplatelet agents. However, these agents induce thrombocytopenia in approximately 1% to 5% of patients, and may lead to bleeding complications. Abciximab is associated with higher incidence of thrombocytopenia than eptifibatide and tirofiban. We describe a case of acute profound thrombocytopenia due to on tirofiban treatment in a patient who underwent primary angioplasty.
No takes yet. Share an insight, caveat, or question.
Dursunoğlu et al. (2013) conducted a case report in Acute profound thrombocytopenia (n=1). Tirofiban was evaluated on Acute profound thrombocytopenia. Tirofiban treatment induced acute profound thrombocytopenia in a patient who underwent primary angioplasty.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: